Raymond Tesi confirmed the Alzheimer's trial data readout is on track for Q2 despite a few extra patients in screening. The recent AbbVie acquisition of Aliada may prompt M&A activity in the Alzheimer's field.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing